Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

NCT07143279

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Jules Bordet Institute
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (3)

- Male hypogonadal with total testosterone \< 231 ng/dl in best supportive care with no further therapeutic options and who do not wish to be reanimated.
- Age e 18 years old
- Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure.

Exclusion (3)

- Untreated prostate cancer, given the risk of epiduritis.
- Known hypersensitivity reactions to the study drug or to any excipients.
- Known allergies to peanuts or soya.

Locations (1 total)

Institut Jules Bordet, Brussels, Belgium